Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeShare-based CompensationShares IssuedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Serina Therapeutics (SER) Cash from Operations (2018 - 2025)

Serina Therapeutics (SER) has disclosed Cash from Operations for 8 consecutive years, with 6078000.0 as the latest value for Q4 2025.

  • Quarterly Cash from Operations fell 32.45% to 6078000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 18000000.0 through Dec 2025, down 5.04% year-over-year, with the annual reading at 18000000.0 for FY2025, 5.04% down from the prior year.
  • Cash from Operations hit 6078000.0 in Q4 2025 for Serina Therapeutics, down from 3822000.0 in the prior quarter.
  • In the past five years, Cash from Operations ranged from a high of 121000.0 in Q4 2023 to a low of 8009000.0 in Q2 2024.
  • Historically, Cash from Operations has averaged 2565850.0 across 5 years, with a median of 1720000.0 in 2021.
  • Biggest five-year swings in Cash from Operations: skyrocketed 109.16% in 2023 and later plummeted 3892.56% in 2024.
  • Year by year, Cash from Operations stood at 1647000.0 in 2021, then rose by 19.79% to 1321000.0 in 2022, then soared by 109.16% to 121000.0 in 2023, then tumbled by 3892.56% to 4589000.0 in 2024, then crashed by 32.45% to 6078000.0 in 2025.
  • Business Quant data shows Cash from Operations for SER at 6078000.0 in Q4 2025, 3822000.0 in Q3 2025, and 3778000.0 in Q2 2025.